It suggests the treatment approach tried with mixed success in recent years isn't the only way to disrupt the disease ‒ and it lays a clear path for what may be a better one. Huntington's ...

The findings suggest that there is a treatment window, potentially decades before symptoms are present, where those at risk of developing Huntington's disease are functioning normally despite ...

MMJ is currently engaged in litigation with the Drug Enforcement Administration (DEA). The company contends that the DEA has ...

New results from an ongoing phase 1/2 study of the therapy showed that it was able to slow down disease progression in patients with early-stage Huntington's over two years compared to an ...

Shares in gene therapy developer uniQure have risen more than 75% after the company reported that Huntington’s disease candidate AMT-130 slowed down the progression of the disorder over two years.

The findings suggest that there is a treatment window, potentially decades before symptoms are present, where those at risk of developing Huntington's disease are functioning normally despite ...

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on QURE stock, giving a Buy rating on January 21.Invest with ...

Log-rolling champ Shana Verstegen's event to raise funds for Huntington's disease research will once again take place at the Monona Terrace on Feb. 15.

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on QURE stock, giving a Buy rating on January 27.Maximize Your ...

The findings suggest that there is a treatment window, potentially decades before symptoms are present, where those at risk of developing Huntington’s disease are functioning normally despite ...

The findings suggest that there is a treatment window, potentially decades before symptoms are present, where those at risk of developing Huntington's disease are functioning normally despite ...